Vittoria Biotherapeutics doses first patient in phase 1 clinical trial of VIPER-101

Vittoria Biotherapeutics announced the first patient dosed in its phase 1 trial of VIPER-101, an autologous cell therapy for relapsed/refractory T cell lymphoma, developed with the Senza5 platform featuring CD5 modulation and a 5-day manufacturing process. The therapy aims to enhance efficacy and safety, offering new hope for patients with limited treatment options.